Edition:
United States

ThromboGenics NV (THR.BR)

THR.BR on Brussels Stock Exchange

3.74EUR
11:38am EDT
Change (% chg)

€-0.19 (-4.78%)
Prev Close
€3.93
Open
€3.92
Day's High
€3.92
Day's Low
€3.74
Volume
290,464
Avg. Vol
40,907
52-wk High
€4.08
52-wk Low
€2.50

Select another date:

Mon, Sep 18 2017

BRIEF-Thrombogenics regains global rights to Jetrea

* THROMBOGENICS NV : THROMBOGENICS REGAINS GLOBAL RIGHTS TO JETREA (OCRIPLASMIN)

BRIEF-Thrombogenics H1 operating loss flat at 15 million euros

* ‍FOR FIRST HALF OF 2017, THROMBOGENICS REPORTED A NET LOSS OF EUR 15.2 MILLION, OR EUR 0.42 PER SHARE​

BRIEF-Oncurious acquires unique portfolio of immuno-oncology assets from VIB

* ONCURIOUS NV ACQUIRES UNIQUE PORTFOLIO OF NEXT-GENERATION IMMUNO-ONCOLOGY ASSETS FROM VIB

BRIEF-Bioinvent and ThromboGenics amending long-standing monoclonal antibody development agreement

* Bioinvent and ThromboGenics amending long-standing monoclonal antibody development agreement

BRIEF-Bioinvent and Thrombogenics amend monoclonal antibody development agreement

* BIOINVENT AND THROMBOGENICS AMENDING LONG-STANDING MONOCLONAL ANTIBODY DEVELOPMENT AGREEMENT

BRIEF-Thrombogenics says Thomas Clay appointed chairman board of directors

* THROMBOGENICS LONG-TIME NON-EXECUTIVE DIRECTOR THOMAS CLAY APPOINTED CHAIRMAN OF THE BOARD OF DIRECTORS

BRIEF-Thrombogenics cash and investments at end of March EUR 73.3 mln

* CASH AND INVESTMENTS WERE EUR 73.3 MILLION AS OF END OF MARCH 2017, COMPARED WITH EUR 80.1 MILLION AT END OF DECEMBER 2016

BRIEF-New Thrombogenics ophthalmic research findings presented at ARVO 2017

* New Thrombogenics ophthalmic research findings presented at ARVO 2017 annual vision research meeting in Baltimore

BRIEF-Thrombogenics achieves important milestone in development of THR-149, novel plasma kallikrein inhibitor for diabetic macular edema

* Achieves important milestone in the development of THR-149, a novel plasma kallikrein inhibitor for diabetic macular edema

Select another date: